DBV Technologies Announces Leadership Changes
09 Septembre 2020 - 7:30AM
DBV Technologies Announces Leadership Changes
Montrouge, France, September 9, 2020
DBV Technologies Announces Leadership
Changes
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that Ramzi Benamar,
Chief Financial Officer, and Kevin Trapp, Chief Commercial Officer,
will be leaving the Company as of October 2, 2020.
Sébastien Robitaille has been appointed as Chief
Financial Officer effective October 2, 2020. Mr. Robitaille joined
DBV in 2015 as Senior VP, Group Controller and Information Systems,
was subsequently named Chief Transformation Officer and Deputy
Chief Financial Officer in 2017, before being promoted to Chief of
Staff to the CEO in 2019.
“Sébastien will be invaluable to DBV in his role
as Chief Financial Officer given his deep understanding of our
business and his role in driving our execution, as well as his
tenure as Deputy Chief Financial Officer,” said Daniel Tassé, DBV’s
Chief Executive Officer. “He has demonstrated experience in leading
the Company through periods of transition, and we believe his
proven acumen will serve him well in this new capacity.”
“On behalf of the entire organization, I would
like to thank Ramzi and Kevin for their significant contributions
to DBV,” said Mr. Tassé. “Ramzi strengthened the DBV balance sheet
in preparation for potential commercial launch and will leave the
Company in a strong cash and financial position. Kevin built a
robust commercial organization and developed a launch strategy for
Viaskin Peanut, if approved. I wish them good luck in their
upcoming endeavors.”
On August 4, 2020, the Company announced that it
had received a Complete Response Letter from U.S. Food and Drug
Administration (FDA) for its Biologics License Application (BLA)
for investigational Viaskin™ Peanut (DBV712), a non-invasive,
once-daily epicutaneous patch to treat peanut allergies in children
ages 4 to 11 years. The Company is preparing a meeting request to
the FDA.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, DBV’s method of delivering biologically active compounds to
the immune system through intact skin. With this new class of
non-invasive product candidates, the Company is dedicated to safely
transforming the care of food allergic patients. DBV’s food
allergies programs include ongoing clinical trials of Viaskin
Peanut and Viaskin Milk, and preclinical development of Viaskin
Egg. DBV is also pursuing a human proof-of-concept clinical trial
of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and
exploring potential applications of its platform in vaccines and
other immune diseases. DBV Technologies has global headquarters in
Montrouge, France and offices in Bagneux, France, and North
American operations in Summit, NJ and New York, NY. The Company’s
ordinary shares are traded on segment B of Euronext Paris (Ticker:
DBV, ISIN code: FR0010417345), part of the SBF120 index, and the
Company’s ADSs (each representing one-half of one ordinary share)
are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Forward Looking StatementsThis
press release may contain forward-looking statements and estimates,
including statements regarding the potential benefits of Viaskin
Peanut and anticipated regulatory interactions. These
forward-looking statements and estimates are not promises or
guarantees and involve substantial risks and uncertainties. At this
stage, the Company’s products have not been authorized for sale in
any country. Among the factors that could cause actual results to
differ materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals,
including the impact of the COVID-19 pandemic. Furthermore, the
timing of any action by the FDA and possible regulatory paths
forward cannot be guaranteed. A further list and description of
these risks, uncertainties and other risks can be found in the
Company’s regulatory filings with the French Autorité des Marchés
Financiers, the Company’s Securities and Exchange Commission
filings and reports, including in the Company’s Annual Report on
Form 20-F for the year ended December 31, 2019, and future filings
and reports by the Company. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements and estimates, which speak only as of the date hereof.
Other than as required by applicable law, DBV Technologies
undertakes no obligation to update or revise the information
contained in this Press Release.
Investor Relations Contact Anne
Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com
Media ContactAngela Marcucci+1
(646) 842-2393angela.marcucci@dbv-technologies.com
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
DBV Technologies (EU:DBV)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024